



## PRESS RELEASE

Stockholm, February 21, 2024

# The Danish company Orphazyme has acquired 10% of the shares in CombiGene

**CombiGene AB (publ) (“CombiGene”, “the Company”) today announces that the Danish company Orphazyme gradually has acquired shares in CombiGene. Today, Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. CombiGene’s Board of Directors have begun a dialogue with Orphazyme.**

For more information on Orphazyme, please visit: [www.orphazyme.com](http://www.orphazyme.com)

### **About CombiGene AB**

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market. The company’s Certified Advisor is FNCA Sweden AB.

### **For more information:**

*CombiGene AB (publ)*

Peter Ekolind, CEO

Tel: +46 (0)70-341 55 60

[peter.ekolind@combigene.com](mailto:peter.ekolind@combigene.com)

Please read “Ingeneious”, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at [www.combigene.com](http://www.combigene.com)